Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options

References

• Guidelines on benign prostatic hyperplasia. European Association of Urology. Internet. 2004. Electronic Citation. www.uroweb.org. Last accessed 2004.
   Google Scholar
• Sagnier PP, McFarlane G, Teillac P, Botto H, Richard F, Boyle P. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995;153:669–673.
   Google Scholar
• Chapple CR. BPH disease management. Eur Urol 1999;36 (Suppl 3):1–6.
   Google Scholar
• Brown C, Yap T, Cromwell D, Rixon L, Steed L, Mulligan K, Mundy A, Newman SP, van der Meulen J, Emberton M. Self management for men with lower urinary tract symptoms: randomized controlled trial. BMJ 2007;334:25–28.
   PubMed Web of Science ®Google Scholar
• Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. New Engl J Med 1995;332:75–79.
   Google Scholar
• Netto NR Jr, de Lima ML, Netto MR, D'Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urol 1999;53:314–316.
   Google Scholar
• Nickel JC. The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Curr Urol Rep 2006;7:282–287.
   Google Scholar
• Morganroth J, Lepor H, Hill LA, Volinn W, Hoel G. Effects of the selective α 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clin Pharmacol Ther 2010;87: 609–613.
   Google Scholar
• Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010;76: 1446–1450.
   Google Scholar
• Roehrborn CG. Efficacy of α-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 2009;11 (Suppl 1):1–8.
   Google Scholar
• Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123–131.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101 (Suppl 3):17–21.
   Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–2398.
   PubMed Web of Science ®Google Scholar
• Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1–13.
   PubMed Web of Science ®Google Scholar
• McNeil SA, Daruwala PD, Mitchel ID, Shearer MG, Hargreave TB. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective placebo-controlled. BJU Int 1999;84:622–627.
   Google Scholar
• Chan PSF, Wong WS, Chan LW, Cheng CW. Can terazosin (α blocker) relieve acute urinary retention and obviate the need for an indwelling urethral catheter? Br J Urol 1996;77 (Suppl 1):27.
   Google Scholar
• Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004;6:31–39.
   PubMedGoogle Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185–1191.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo-controlled study. The Scandinavian BPH study group. Urology 1995;46:631–637.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial (the PROSPECT Study). CMAJ 1996;155:1251–1259.
   PubMed Web of Science ®Google Scholar
• Vaughan D, Imperato-McGinley J, McConnell J, Matsumoto AM, Bracken B, Roy J, Sullivan M, Pappas F, Cook T, Daurio C, Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002;60:1040–1044.
   PubMed Web of Science ®Google Scholar
• Ekman P. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-extension Study. The Scandinavian Finasteride Study Group. Eur Urol 1998;33:312–317.
   Google Scholar
• Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003;61:354–358.
   PubMed Web of Science ®Google Scholar
• Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Effect of finasteride on bother and other healthrelated quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999;54:670–678.
   Google Scholar
• Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, Meehan A, Stoner E, Waldstreicher J. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000;38:563–568.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Guess HA, Epstein JL, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998;52:195–201.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192–1202.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999;53:696–700.
   PubMedGoogle Scholar
• Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009;73:935–939.
   PubMed Web of Science ®Google Scholar
• Kirby RS, RoehrbornC, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB; Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazocin and Combination Therapy (PREDICT) trial. Urology 2003;61:119–126.
   PubMed Web of Science ®Google Scholar
• Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58:203–209.
   PubMed Web of Science ®Google Scholar
• Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. α-Blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-α reductase inhibitor dutasteride. Eur Urol 2003;44:461–466.
   PubMed Web of Science ®Google Scholar
• Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. Impact of delaying 5-α reductase inhibitor therapy in men on α-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. Curr Med Res Opin 2009;25:2663–2669.
   PubMed Web of Science ®Google Scholar
• Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol 2006;8:183–189.
   PubMedGoogle Scholar
• Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? Br J Urol 1999;83:227–237.
   Google Scholar
• Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG; Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 2008;180:246–249.
   PubMed Web of Science ®Google Scholar
• Poulakis V, Dahm P, Witzsch U, Sutton AJ, Becht E. Transurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysis. BJU Int 2004;94:89–95.
   PubMed Web of Science ®Google Scholar
• Botto H, Lebret T, Barrι P, Orsoni JL, Hervi JM, Lugagne PM. Electrovaporization of the prostate with the Gyrus device. J Endourol 2001;15:313–316.
   PubMed Web of Science ®Google Scholar
• Ho HS, Yip SK, Lim KB, Fook S, Foo KT, Cheng CW. A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system. Eur Urol 2007;52:517–522.
   PubMed Web of Science ®Google Scholar
• Fagerstrom T, Nyman CR, Hahn RG. Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique: a single-centre randomized trial of 202 patients. BJU Int 2010;105:1560–1564.
   PubMed Web of Science ®Google Scholar
• Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol 2001;165: 1526–1532.
   PubMed Web of Science ®Google Scholar
• Lourenco T, Shaw M, Fraser C, MacLennan G, N'Dow J, Pickard R. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World J Urol 2010;28:23–32.
   Google Scholar
• Lü J, Hu W, Wang W. Sonablate-500 transrectal high-intensity focused ultrasound (HIFU) for benign prostatic hyperplasia patients. J Huazhong Univ Sci Technol Med Sci 2007;27:671–674.
   Google Scholar
• Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol 2000;37:687–694.
   PubMed Web of Science ®Google Scholar
• Schatzl G, Madersbacher S, Lang T, Marberger M. The early postoperative morbidity of transurethral resection of the prostate and of four minimally invasive treatment alternatives. J Urol 1997;158:105–110.
   Google Scholar
• Bouza C, López T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 2006;6:14–30.
   PubMedGoogle Scholar
• Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003;44:89–93.
   PubMed Web of Science ®Google Scholar
• Stovsky M, Griffiths R, Duff S. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. J Urol 2006;176:1500–1506.
   PubMedGoogle Scholar
• Kaye JD, Smith AD, Badlani GH, Lee BR, Ost MC. High-energy transurethral thermotherapy with CoreTherm approaches transurethral prostate resection in outcome efficacy: a meta-analysis. J Endourol 2008;22:713–718.
   PubMed Web of Science ®Google Scholar
• Masood S, Djaladat H, Kouriefs C, Keen M, Palmer JH. The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int 2004;94:1271–1274.
   Web of Science ®Google Scholar
• Goepel M, Senge A, Otto T, Rübben H. Long-term results of wall stent implantation in benign prostatic hyperplasia and high risk status. Urologe A 1997;36:151–156.
   Google Scholar
• Grimsley SJ, Khan MH, Lennox E, Paterson PH. Experience with the spanner prostatic stent in patients unfit for surgery: an observational study. J Endourol 2007;21:1093–1096.
   Web of Science ®Google Scholar
• Cowles RS, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B, Zabbo A. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 1995;46:155–160.
   PubMed Web of Science ®Google Scholar
• Abdel-Khalek M, El-Hammady S, Ibrahiem el-H. A 4-year follow-up of a randomized prospective study comparing transurethral electrovaporization of the prostate with neodymium: YAG laser therapy for treating benign prostatic hyperplasia. BJU Int 2003;91:801–805.
   Google Scholar
• Karatas OF, Alkan E, Horasanli K, Luleci H, Sarica K. Photoselective vaporization of the prostate in men with a history of chronic oral anti-coagulation. Int Braz J Urol 2010;36:190–197.
   Google Scholar
• Bouchier-Hayes DM, Van Appledorn S, Bugeja P, Crowe H, Challacombe B, Costello AJ. A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int 2010;105:964–969.
   PubMed Web of Science ®Google Scholar
• Hai MA. Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population. Urology 2009;73: 807–810.
   Google Scholar
• Suardi N, Gallina A, Salonia A, Briganti A, Dehò F, Zanni G, Abdollah F, Naspro R, Cestari A, Guazzoni G, Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. Curr Opin Urol 2009;19:38–43.
   Google Scholar
• Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, Valenti S, Vavassori I, Rigatti P. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol 2004;172:1926–1929.
   PubMed Web of Science ®Google Scholar
• Westenberg A, Gilling P, Kennett K, Frampton C, Fraundorfer M. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term follow-up. J Urol 2004;172:616–619.
   Google Scholar
• Naspro R, Suardi N, Salonia A, Scattoni V, Guazzoni G, Colombo R, Cestari A, Briganti A, Mazzoccoli B, Rigatti P, Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. Eur Urol 2006;50:563–568.
   PubMed Web of Science ®Google Scholar
• Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm: a randomized prospective trial of 120 patients. J Urol 2002;168:1465–1469.
   Web of Science ®Google Scholar
• Gupta N, Sivaramakrishna, Kumar R, Dogra P, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 2006;97:85–89.
   PubMed Web of Science ®Google Scholar
• Elzayat E, Habib E, Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 2006;175:1428–1432.
   Google Scholar
• Gilling PJ, Aho TF, Frampton CM, King CJ, Fraundorfer MR. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol 2008;53:744–749.
   Web of Science ®Google Scholar
• Cornford PA, Biyani CS, Powell CS. Transurethral incision of the prostate using the holmium:YAG laser: a catheterless procedure. J Urol 1998;159:1229–1231.
   Google Scholar
• Kursh ED, Concepcion R, Chan S, Hudson P, Ratner M, Eyre R. Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: a randomized trial with 2-year follow-up. Urology 2003;61:573–578.
   PubMed Web of Science ®Google Scholar
• Liedberg F, Adell L, Hagberg G, Palmqvist IB. Interstitial laser coagulation versus transurethral resection of the prostate for benign prostatic enlargement – a prospective randomized study. Scand J Urol Nephrol 2003;37:494–497.
   PubMed Web of Science ®Google Scholar